ARTICLE IN PRESS

American Journal of Infection Control 000 (2020) 1-5



Contents lists available at ScienceDirect

American Journal of Infection Control



journal homepage: www.ajicjournal.org

Brief Report Halting a SARS-CoV-2 outbreak in a US Veterans Affairs nursing home

George Psevdos MD^{a,*}, Aikaterini Papamanoli MD^b, Nancy Barrett RN, MS, CIC^c, Lisa Bailey RN, BSN, MS, CIC^c, Monique Thorne EdD, MS, RN-BC^c, Florence Ford RN, BSN, MSN^c, Zeena Lobo MD^a

^a Division of Infectious Diseases, Veterans Affairs Medical Center, Northport, NY

^b Department of Infectious Diseases, Stony Brook University Hospital, Stony Brook, NY
^c Division of Nursing, Infection Control, Veterans Affairs Medical Center, Northport, NY

Division of Nursing, injection Control, veteruns Afjuns Medical Center, Northport, N

Key Words: Long term care facilities Coronavirus COVID-19 A Veterans Affairs long term care facility on Long Island New York was confronted with a COVID-19 outbreak in late March to Mid-April 2020. Faced with a dwindling supply of PPE, the Infection Control team distributed supplies saved for a possible Ebola outbreak. A COVID unit was created within the nursing home facilitating the geographic isolation of cases; universal testing of residents and employees allowed for the implementation of proper quarantine measures. It was a multidisciplinary team approach led by the Infection Control team that successfully contained this outbreak.

© 2020 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved.

Since the first cases reported in December 2019, infection with the severe acute respiratory coronavirus 2 (SARS CoV-2) has become a worldwide pandemic. The disease caused by this novel virus, the Corona Virus Disease-2019 (COVID-19) has overwhelmed health care systems globally. The World Health Organization declared COVID-19 a pandemic on March 11, 2020.¹ The pandemic was first recognized in the United States in Washington State, involving an outbreak in a skilled nursing facility; currently confirmed cases exceed 7 million.^{2,3} Eventually, multiple outbreaks caused by the novel coronavirus quickly emerged in long-term care and assisted living facilities worldwide. Elderly patients are particularly vulnerable and susceptible to adverse clinical outcomes of COVID-19 including respiratory failure and death.⁴ According to the Nursing Home COVID-19 Public File from data reported by nursing homes to the Centers for Disease Control and Prevention's (CDC) National Healthcare Safety Network, of 207,315 cases in the US nursing homes, 51,700 deaths (25%), have been reported.⁵ In a review of over 9,000 nursing homes from the United States, COVID-19 outbreaks were more related to facility size, location--with Massachusetts and New Jersey having the greatest number of affected facilities-and greater percentage of African American residents.⁶ The last mentioned fact mirrors a critical health disparity seen in this pandemic at large, namely African Americans

* Address correspondence to George Psevdos, M.D. Chief of infectious diseases, Clinical Associate Professor of Medicine, Division of infectious diseases Northport Veterans Affairs Medical Center, 79 Middleville Rd, Northport, NY 11768.

E-mail address: george.psevdos@va.gov (G. Psevdos). Conflicts of interest: None to report. contracting SARS CoV-2 at higher rates and are more likely to die.⁷ Although nationally the virus spreads like wildfire in nursing homes (among residents and working staff), the Department of Veterans Affairs (VA) reported lower COVID-19 rates in their affiliated nursing homes in a US Congressional hearing.⁸ We discuss here our experience in facing a COVID-19 outbreak in our VA affiliated nursing homes.

METHODS

Northport Veterans Affairs Medical Center provides hospitalbased acute medical and psychiatric care for US Veterans, as well as long-term/extended nursing home and residential mental health program care. The nursing homes are structured as community living centers (CLCs), with a 139 total bed capacity. There are 4 CLCs, CLC1-4, which include mental health (CLC3) and hospice care units (CLC4). The COVID-19 outbreak involved CLC 1 and CLC2, both totaling 80 beds. Veterans are eligible to live in the CLCs if they have service-connected disability (70% or more)-a disability assigned to them by the Department of VA based on injury or illness that incurred, or, was aggravated during active military service. CLC 1 and 2 units admit Veterans with complex underlying medical issues that can include immobility due to stroke and cardiovascular disease, continuous oxygen requirement due to chronic obstructive lung disease, end stage renal disease on dialysis, complex wound care, chemotherapy, prolonged intravenous antibiotic therapy, and other rehabilitation needs.

0196-6553/© 2020 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved.

2

ARTICLE IN PRESS

G. Psevdos et al. / American Journal of Infection Control 00 (2020) 1-5

We performed an observational single-site study to achieve an epidemiological understanding of the COVID-19 outbreak in our facility between March 24 to April 18, 2020. We reviewed the electronic medical records of the infected CLC residents, and we obtained the following data: age, demographic information, medical history, presenting symptoms and vitals, radiographic and laboratory data, and bed location of the patients in the CLCs at the time of COVID-19 diagnosis. Antibiotic choices and outcomes were recorded. Dichotomous and categorical variables were compared using chi square test or Fisher's exact test. All data during the outbreak were collected as part of the facility's healthcare epidemiology process by our infection control/infectious diseases specialists, in an effort to control the outbreak. We also describe the implemented preventive measures and their impact on containing the outbreak. The study was approved by the Institutional Review Board.

Every CLC resident who either developed a temperature of >99° F with or without symptoms of respiratory illness and tested positive for SARS-CoV-2 by nasopharyngeal or sputum reverse transcription polymerase chain reaction (RT-PCR), or was asymptomatic and screened positive by RT-PCR, was defined as a case of COVID-19. Health care workers were defined as probable COVID-19 cases if they had respiratory symptoms during the outbreak period, whereas definite cases required a positive RT-PCR. In the beginning our PT-PCR tests were performed at the VA Public Health Reference Laboratory in Palo Alto California (utilizing the CDC's RT-PCR test) and the turnaround time was 3-4 days. By March 30th we started utilizing the rapid RT-PCR Cepheid, Sunnyvale, CA. The turnaround time was 1 hour. The first identified cases were a CLC resident and a health care provider (HCP) and were diagnosed on the same day, March 24th. Figure 1 shows the tests performed by date; positive and negative results for residents and positive results for HCP are included. Figure 2 illustrates the CLC 1 and CLC 2 outline of beds indicating positive cases in sequence of detection. Initial spread of the virus was fast, affecting residents and health care workers.

The infection control team in our organization, consists of 4 facility-wide infection control nurses; a nurse manager, a multidrug resistant organisms expert and 2 infection control preventionists. Understandably, during this period, their primary focus was halting and containing the SARS-CoV-2 outbreak.

INFECTION CONTROL MEASURES

The Department of Veterans Affairs Deputy Under Secretary for Health for Operations and Management sent a Memorandum on March 17th providing updated guidance for CLCs, which we followed throughout the outbreak. Initially and in preparation for a possible outbreak we restricted all visitations to the CLCs, except for compassionate care situations, such as an actively dying Veteran. Infection control preventionists educated the residents and staff on the new Coronavirus. Guidance to screen all residents for signs/symptoms of COVID19 daily was implemented. All staff entering the CLCs had temperature checks and were also screened for signs and symptoms of COVID 19.

After the first case was identified, abiding by the above-mentioned guidance, we initially implemented social distancing and isolation practices. All resident group activities and communal dining were permanently halted, floating of staff between units minimized as feasibly as possible, new admissions to the units were stopped. Residents were requested to stay in their rooms; if exiting their room, they were educated to wear a mask and follow proper respiratory etiquette. Hand hygiene was also enforced, as well as education on proper use of personal protective equipment (PPE) by the infection preventionists on their daily environmental rounds. Symptomatic employees including asymptomatic who were screened positive were requested to self-isolate at home. Symptomatic residents with fever or respiratory symptoms (including cough, dyspnea) were placed in a single room, the doors were to remain closed and geriatricians were requested to stop nebulized treatments. Alternatively, they could use Meter Dose Inhaler's, if that was feasible, as per CDC recommendations. As RT-PCR results were initially delayed, these residents were considered "patients under investigation" and droplet/contact precautions with proper PPE was required to enter their



SARS-CoV-2 Outbreak Dates of Tests

Fig 1. SARS-CoV-2 outbreak dates of tests.

ARTICLE IN PRESS

G. Psevdos et al. / American Journal of Infection Control 00 (2020) 1-5



Fig 2. Outline of CLCs and COVID-19 cases.

rooms, focusing on containing and even stopping the spread of SARS-CoV 2.

Increased demand and utilization of the appropriate PPE can quickly deplete resources and pose operational dilemmas to health care facilities. As part of contingency strategies in resource utilization, the infection control team inventoried the facility's stored supplies. The team, distributed PPE originally saved for an Ebola outbreak to the health care teams in the emergency room and dedicated COVID units. These included whole body suits, head and neck coverings, booties/shoe coverings, and N95 respirators. This initiative from the infection control team helped in providing solidarity and improving the treatment experience for our colleagues working in the nursing homes.

On April 2nd the Center for Medicare and Medicaid Services recommended screening of all nursing home residents and cohorting of staffing teams for infected and uninfected patients.⁹ By April 3rd with the help of the Engineering department, a geographic and staff cohort was constructed and a dedicated COVID unit was created inside the CLC1. This COVID unit had newly placed double doors that remained closed, an anteroom, and donning and doffing areas. The rapid RT-PCR test was eventually used, which contributed to early identification and relocation of COVID 19 cases into this unit. Neighboring asymptomatic residents were tested first, and by April 17th all residents of CLC 1 and 2 along with health care members were screened for SARS-CoV-2 in accordance with the CDC's American Testing Guidance for Nursing Homes.¹⁰ Universal masking and temperature checks were required for every employee entering the CLCs throughout this period. Withdrawal of COVID-19 isolation precautions required resolution of symptoms, and two sequential negative nasopharyngeal RT-PCR tests which were obtained after 14 days from diagnosis. If the RT-PCR test was positive, a repeat test was obtained in 72 hours.

RESULTS

We were able to halt the spread of the disease over a 3-week period. The first patient was identified in CLC1. He developed fever and cough on March 24th, the test was obtained the same day and resulted positive on March 27th; he was then transferred to the VA Medical Center in our campus. The fourth patient had tested negative on March 20th but was hospitalized on March 23rd for febrile illness and was diagnosed with *Klebsiella pneumonia* bacteremia. During his admission he became hypoxic, was retested and was positive on March 27th. Overall, only 25 out of 80 (31%) CLC residents were tested positive for SARS-CoV-2 infection. The initial spread was rapid with the first 12 cases being diagnosed over a period of 8 days, by March 31st. Our measures including the creation of a dedicated COVID unit, the use of rapid RT-PCR test, and universal testing lead to a decline in cases and finally to a full resolution of the outbreak by April 18th. Of the total 25 patients, 5 remained asymptomatic, 9 were

4

ARTICLE IN PRESS

G. Psevdos et al. / American Journal of Infection Control 00 (2020) 1-5

Table 1

Demographics, laboratory findings, outcomes of COVID-19 CLC cohort

Metange years(ange)7(88-90)7(48-87)0.105Caucasian9960.000Caucasian9960.020Caugab, #750.020Dyspera, #00 (394-104)102.3(975-104.6)0.338Median Earg F(range)00 (394-104)102.3(975-104.6)0.338Median Earg tarke bom, (range)107 (394-104)102.3(975-104.6)0.036Median Heart Rate bom, (range)181-133)102 (55-122)0.036Median Heart Rate bom, (range)181-133)261.9-14.00.031My (range)261.9-200.0180.030Median Heart Rate bom, (range)216.9-6030.030My (range)261.9-14.00.0310.030Dysper struction on Rom Air, %22(84-96)86.030.030COPD, #11.0000.0401.0000.040COPD, #530.0300.0410.031Upbatets, #11.0000.0400.0400.040COPD, #530.0400.0400.040COPD, #630.0400.0400.040Updroxtoniconine, #11.0000.0400.0400.040Authormycin, #630.0400.0400.040Authormycin, #611.0000.0400.040Authormycin, #11.0001.0400.00000.0000Median Death Card, #11.0000.00000.00000.00		COVID-19 recoverd N = 19	COVID-19 deceased N = 6	<i>P</i> value
MenI861.000CaucasianI950.240Cough,#750.073Cough,#102 (93-104)12.3 (97.5-104.6)0.338Median Erom YF (range)102 (93-104)102 (77.154)0.246Median Karan Kate bpn, (range)81 (81-153)102 (77.154)0.0005Median Karan Kate bpn, (range)26 (13-29)0.0180.0005BMI (range)26 (13-29)26 (10-41)0.911Dysgen strutation on Rom Air, %686 (70-92)0.018Dysgen strutation on Rom Air, %1210001000CPD, #510.0000.018Dysgen strutation on Rom Air, %630.630Dysgen strutation on Rom Air, %1210.0000.018CPD, #50.0010.0000.000CAD, #11.0000.0000.000CAD, #11.0000.0000.000CAD, #11.0000.0000.000CAD, #11.0000.0000.000CAD, #11.0000.0000.000CAD, #11.0000.0000.000Air from Canad Respectively NEG66.0000.000Muthor basylialized11.0000.000Air from Canad Respectively NEG6.0000.0000.000Median Attrutation Right10.0000.0000.000Median Mathibision Right10.0001.0000.000Median Definet on Admi	Median age years(range)	77 (68-90)	73 (48-87)	0.105
Caucsin1950.240Cough, #760.073Dyspne, #102 (94-104)10.23 (97.5-104.6)0.33Median Exprirtancy Transpe)9 (93-112)102 (77-154)0.246Median Exprirtancy rate breaths/min18 (18-153)102 (65-122)0.035Median Exprirtancy rate breaths/min18 (19-20)24 (15-26)0.031Median Exprirtancy rate breaths/min18 (19-20)24 (15-26)0.031Median Exprirtancy rate breaths/min12 (13-20)0.0180.031Dysgen statuation on Room Air, %92 (84-96)86 (70-92)0.018Dysgen statuation on Room Air, %1241.000Upsgen statuation on Room Air, %121.0000.018Dysgen statuation on Room Air, %50.0130.014Dysgen statuation on Room Air, %121.0000.014Dysgen statuation on Room Air, %50.0130.014Dysgen statuation on Room Air, %120.0010.010ChUP, #50.0140.0010.010ChUP, #120.0141.0000.013ChUP, #120.0141.0000.010ChUP, #120.0141.0000.010ChUP, #120.0141.0000.010Dyschild, #120.0141.0000.010Dyschild, #120.0141.0000.010ChUP, #120.0141.0000.010Dyschild, #120.014 <td< td=""><td>Men</td><td>18</td><td>6</td><td>1.000</td></td<>	Men	18	6	1.000
Cough, #750.073Dyspnea, #102 (94-104)102 (97.5-104.6)0.338Median SRP mink france)102 (94-104)102 (37.5-104.6)0.338Median Rem rink france)102 (95-122)0.036Median Rem rink france)18 (18-153)102 (65-122)0.036Median Resprint on noom Air, %26 (13-29)26 (13-20)0.018Dysgen statution noom Air, %29 (24-96)86 (70-92)0.018Dysgen statution noom Air, %29 (24-96)87 (70-92)0.018Dysgen statution noom Air, %29 (24-96)10000.000CMP, #31.0000.000CMP, #530.030Hypertension, #11.0000.030CMP, #130.030Phore thospitalized2 and srespectively, NEG63Mendian Resprint R	Caucasian	19	5	0.240
pypene, #140.05Median Carr (Frage)9(93-112)122 (975-104.6)3.33Median BSP mnHg (range)9(93-112)102 (77-154)0.236Median Haer Karb pun (range)8 (181-153)102 (65-122)0.036Median Respiratory rate breaths/min18 (19-29)24 (15-26)0.033Dygen saturation on Room Air, %92 (84-96)86 (70-92)0.018Diabetes, #630.630Hypertension, #11.0000.018CVDP, #521.0000.014CVDP, #530.630CAD, #530.630Muther hospitalized630.630Muther hospitalized630.630Muther hospitalized12 and a respectively.NEG60.000CAD, #11.0000.3020.010Distory of CEL/AB use11.0000.3020.010Distory of CEL/AB use11.0000.3020.010Median Dear Mathibitis, #11.0000.3020.010Median Dear Mathibitis, #11.0000.3020.010Median Dear Mathibitis, #11.0000.3020.010Median Dear Mathibitis, #0.1011.0000.0000.000Median Dear Mathibitis, #0.1010.252 (497-3039)0.019Median Dear Mathibitis, #0.1010.5230.0420.002Median Dear Mathibitis, #1.000352 (497-3039)0.019 <td>Cough, #</td> <td>7</td> <td>5</td> <td>0.073</td>	Cough, #	7	5	0.073
Median Erm PF (range)102 (994-104)102 (977-154)0.236Median Erm Mitkg (range)81 (81-13)102 (65 -122)0.036Median Heart Bate bro, (range)81 (81-13)102 (65 -122)0.036Median Respiratory rate breaths/min81 (92-20)26 (15-26)0.037BM (range)26 (13-20)26 (15-26)0.038Daygen saturation on Room Air, %92 (84-96)86 (70-92)0.018Daybetes, #630.6530Hypertension, #1241.000CHF, #311.000COPD, #520.018Mumber hospitalized630.6334Hemodialysis, #110.430Number hospitalized630.630ationnycin, #12 and respectively.NEG6 and respectively.NEGAutomycin, #12 and respectively.NEG6.000Automycin, #11.0000.000Automycin, #530.600Petrolady Eresult11.0000.000Automycin, #010.240History of ACEI/ARB use411.000Median D-Minero399 (150-225)325 (497-3039)0.019Median PEAK D-Dimer405 (150-2339)259 (897-3039)0.002Median PEAK D-Dimer12 (150-03064 (385-1500)0.158Median PEAK D-Dimer31 (35 (15-150)0.2401.58Median PEAK D-Dimer12 (1500)64 (385-1500)0.012Median PEAK	Dyspnea, #	1	4	0.005
Median BP mmtlg (mage)99 (93-12)102 (77-154)0.246Median Respiratory rate breaths/min18 (19-29)24 (15-26)0.038BM (range)26 (13-29)26 (19-20)0.018Dyagen saturation on Roam Air, %29 (84-56)86 (70-92)0.018Diabetes, #630.633Phypertension, #1241.0000CHP, #310.003CAD, #530.034Hennodialysis, #110.430Number hospitalized630.630Vertinsyn, #12 and 3 respectively. NEG0.6300.630CAD, #110.4300.630Number hospitalized630.630Vertinsyn, #12 and 3 respectively. NEG0.6300.630Acithmycin, #12 and 3 respectively. NEG0.00000.0000Acithmycin, #130.00000.0000Acithmycin, #630.0000Median Acith Yangen, #10.00000.0000Median Acith Yangen, #010.240History of ACEI/AB use410.0000Median Proceictonin ng/mL399 (150-226)152 (497-303)0.0019Median Proceictonin ng/mL399 (150-226)152 (497-303)0.0019Median Proceictonin ng/mL399 (150-226)152 (497-303)0.0019Median Proceictonin ng/mL16 (1-1500)64 (385-1500)0.012Median Proceictonin ng/mL16 (1-1500)6	Median Temp °F (range)	102 (99.4-104)	102.3 (97.5-104.6)	0.338
Median karit karit bynr18 (19-30)102 (65 - 122)0.036Median kapitatory rate breaths/min18 (19-29)24 (15-26)0.003DW (range)26 (13-20)26 (19-41)0.591Oxygen saturation on Room Air, %92 (84-96)86 (70-92)0.018Diabetes, #110.000(HT, #1241.000COPD, #520.034COPD, #530.630Hymernsion, #630.630COPD, #530.630Homodialysis, #10.4340.630# of influenza tests, viral panels, result130.630# of influenza tests, viral panels, result130.600Azithromycin, #630.600Doxycycline, #630.600Betra datam antibiotics, #530.400Median REAK D-Dimer630.400Median REAK D-Dimer4500.00090.0009Median REAK D-Dimer4500.00090.0009Median REAK D-Dimer4510-0.00090.00090.0002Median REAK D-Dimer136 (19-0.300)0.64 (33-5100)0.013Median REAK D-Dimer136 (19-1500)385 (249-1500)0.013Median REAK D-Dimer136 (19-1500)385 (249-1500)0.002Median REAK Procalcionin ng/mL136 (19-1500)385 (249-1500)0.013Median REAK Procalcionin ng/mL136 (19-1500)385 (249-1500)0.013 <t< td=""><td>Median SBP mmHg, (range)</td><td>99 (93-112)</td><td>102 (77-154)</td><td>0.246</td></t<>	Median SBP mmHg, (range)	99 (93-112)	102 (77-154)	0.246
Median Respiratory rate breaths/min18 (19-29)24 (15-26)0.003DMI (range)26 (13-27)66 (19-41)0.551Doygen saturation on Room Air, %92 (84-96)86 (70-92)0.018Diabetes, #630.630Hypertension, #1241.000CHP, #311.000CAD, #520.018Henodialysis, #110.034Henodialysis, #130.434Number hospitalized630.630Very Architek, #12 and 3 respectively, NEG6 and 3 respectively, NEGHydroxychioroquine, #12 and 3 respectively, NEG0.600Azithromycin, #630.000Azithromycin, #010.340Doxycychine, #630.600Betraidsgue, #010.240History of ACEI/ARB use410.000Median ASPI Is core320.6000.000Median Procalcitonin ng/mL on Admission0.10.255 (887-303)0.019Median REM Fronzinon Minison ng/mL136 (19-1500)64 (38-1500)0.158Median REAK Ferritin136 (19-1500)64 (38-1500)0.163Median REAK Ferritin136 (19-1500)64 (38-1500)0.032Median REAK Ferritin136 (19-1500)64 (38-1500)0.032Median REAK Ferritin136 (19-1500)64 (38-1500)0.032Median REAK Ferritin106 (19-27)0.0020.002	Median Heart Rate bpm, (range)	81 (81-153)	102 (65 –122)	0.036
BMI (range)26 (13-29)26 (19-41)0.591Diabetes, #630.6300Hypertension, #1241.0000CMP, #1241.0000COPD, #520.6301CMP, #530.6301Mumber hospitalized630.6302# of influenza tests, viral panels, result10.4304Hydroxychloroquine, #130.6302# of influenza tests, viral panels, result12 and 3 respectively, NEG6 and 3 respectively, NEGHydroxychloroquine, #1130.6000Acithromycin, #630.6000Doxycycline, #630.6000Doxycycline, #630.6000Steroids given, #010.2400Median D-Gimeron admission ng/mL39 (150-226)1552 (497-3039)0.0193Median PEAK D-Dimer465 (150-2339)2592 (887-3039)0.0005Median PEAK D-Dimer465 (150-2339)2592 (887-3039)0.0005Median PEAK D-Dimer465 (150-2339)2592 (887-3039)0.0033Median PEAK RP1174<0.001	Median Respiratory rate breaths/min	18 (19-29)	24 (15-26)	0.003
Oxygen sturation on Room Air, %28(84-96)8(70-92)0.018Diabetes, #630.630Hypertension, #1241.000CHF, #311.000COPD, #521.000CAD, #530.344Hemodialysis, #110.430Number hospitalized66 and 3 respectively, NEG6 and 3 respectively, NEGHydroxychloroquine, #1130.6600Oxycycline, #630.600Deta lactam antibiotics, #630.600Beta lactam antibiotics, #630.340Steroids given, #010.200Median D-dimer on admission ng/mL39(150-2226)152 (497-3039)0.0005Median ASPL Rocalcitonin ng/mL on Admission0.110.250.042Median ASPL Rocalcitonin ng/mL on Admission0.110.250.0015Median ASPL Rocalcitonin ng/mL on Admission3.3 (150-10)0.1580.0135Median ASPL Rocalcitonin ng/mL on Admission3.4 (15-100)0.0020.0015Median PEAK CRP4615000.0230.0025Median PEAK CRP136 (19-1500)38 (249-1500)0.158Median PEAK CRP136 (19-1500)64 (435-1500)0.158Median PEAK CRP136 (19-1500)64 (435-1500)0.023Median REAK Ferritin3.3 (3.5-105.0)6.4 (43-25.1)0.230Median NEAK Ferritin3.3 (3.5-105.0)6.4 (43-5.0)0.158 <td>BMI (range)</td> <td>26 (13-29)</td> <td>26(19-41)</td> <td>0.591</td>	BMI (range)	26 (13-29)	26(19-41)	0.591
Diabetes, #6366Hypertension, #1241.000CHF, #311.000COPD, #521.000CAD, #530.344Hemodialysis, #630.344Hemodialysis, #12 and 3 respectively, NEG6 and 3 respectively, NEG# of influenza tests, viral panels, result2 and 3 respectively, NEG6Hydroxychiconquine, #131.000Azithromycin, #630.630Doxycycline, #630.600Beta lactan antibiotics, #530.340Steroids given, #630.340Netian Arbitopic given, #630.340Netian Arbitopic given, #610.0009Median CHC/RAB use411.000Median Peter on admission ng/mL396 (150-2236)1525 (497-3039)0.019Median Peter Proalcitonin ng/mL on Admission0.10.250.042Median Peter Proalcitonin ng/mL216 (19-100)352 (249-1500)0.158Median Peter Proalcitonin ng/mL216 (19-1500)64 (332-1500)0.031Median Peter Provintion on g/mL216 (19-1500)64 (332-5100)0.047Median Peter Peter Intion on dmission ng/mL216 (21-1500)64 (332-5100)0.047Median Peter Peter Intion on g/mL216 (21-1500)64 (332-5100)0.047Median Peter Peter Intion on g/mL216 (21-1500)64 (332-5100)0.047 <t< td=""><td>Oxygen saturation on Room Air, %</td><td>92 (84-96)</td><td>86 (70-92)</td><td>0.018</td></t<>	Oxygen saturation on Room Air, %	92 (84-96)	86 (70-92)	0.018
Hypertension, #1241.000CHF, #311.000CAP, #521.000CAD, *530.344Hemodialysis, #110.430Number hospitalized630.363Periodial tests, viral panels, result12 and 3 respectively, NEG6 and 3 respectively, NEGHydroxychloroquine, #1131.000Azithromycin, #630.600Doxycycline, #630.340Doxycycline, #010.240Histomycin, #010.240Histomycin, #010.240Histomy of ACEI/ARB use399 (150-226)1525 (497-3039)0.019Median PEAK D-Dimer663 (150-2339)2592 (887-3039)0.0003Median PEAK D-Dimer663 (150-2339)2592 (887-3039)0.003Median PEAK Procalcionin0.10.250.422Median PEAK Procalcionin0.10.250.424Median PEAK Procalcionin150 (89-290)0.6160.510Media	Diabetes, #	6	3	0.630
CFF, #311,000COPD, #521,000COPD, #530.344Hemodalysis, #110.430Number hospitalized630.630# of influenza tests, viral panels, result12 and 3 respectively, NEG6 and 3 respectively, NEGHydroxychloroquine, #1131.000Azithromycin, #630.660Doxycycline, #630.600Beta lactam athibitics, #530.340Steroids given, #010.240History of ACEI/ARB use410.0009Median D-dimer on admission ng/mL399 (150-2320)1525 (497-3039)0.019Median PEAK Procalcitonin ng/mL, 00.10.250.042Median PEAK Procalcitonin ng/mL16 (19-530)0.1580.018Median PEAK Procalcitonin ng/mL13 (19-1500)385 (249-1500)0.158Median PEAK Procalcitonin1.10(7-6.5)1.8 (0.8-6.3)0.031Median PEAK Protine on Admission ng/mL13 (19-1500)385 (249-1500)0.047Median PEAK Procalcitonin1.10(7-6.5)1.8 (0.8-6.3)0.031Median PEAK Protine on Admission ng/mL1.5 (9.8-7.90)0.023Median PEAK Protine on Admission ng/mL1.5 (9.8-7.90)0.023Median PEAK Protine on Admission ng/mL1.5 (9.9-7.90)0.64 (199-3.20)0.047Median PEAK Protine on Admission ng/mL1.5 (9.9-7.90)0.2100.312Median PEAK Protine on Admissi	Hypertension, #	12	4	1.000
COPD, #521.000CAD, #530.344Hemodialysis, #10.4300.344Number hospitalized630.304Wernber hospitalized63.00.800# of influenz tests, viral panels, result12 and 3 respectively, NEG6 and 3 respectively, NEGHydroxychloroquine, #131.000Arithromycin, #630.600Doxycycline, #630.600Beta lactam antibiotics, #010.240History of ACEI/AB use90 (150-2226)1525 (497-3039)0.019Median ASP Is la core320.00090.0009Median PEAK Proclacitonin ng/mL0.10.250.002Median PEAK Proclacitonin ng/mL16 (19-233)0.0190.019Median PEAK Proclacitonin ng/mL136 (19-1500)64 (38-51500)0.014Median PEAK Proclacitonin ng/mL136 (19-1500)64 (38-5150)0.312Median PEAK CRP1.1 (0.7-66)7.05-1.0)0.312Median Serum Creatinine mg/dL1.1 (0.7-66)8 (0.8-6.3)0.1032Median Serum Creatinine mg/dL1.00 (50-2.00)0.0020.002Median Serum Creatinine mg/dL1.00 (50-2.00)0.002Median Serum Creatinine mg/dL1.00 (50-2.00)0.002Median Serum Creatinine mg/dL1.00 (50-2.00)0.002Median Serum Creatinine mg/dL1.00 (50-2.00)0.002Median Serum Creatinine mg/dL1.00 (50-2.00)0.002	CHF, #	3	1	1.000
CAD. #530.344Hemodialysis, #110.343Humber hospitalized630.630# of influenza tests, viral panels, result12 and 3 respectively, NEG6 and 3 respectively, NEGHydroxychloroquine, #420.660Doxycycline, #630.600Beta lactam attibiotics, #530.300Steriolds given, #010.200History of ACE[/ARB use410.300Median D-Gimer on admission ng/mL399 (150-226)1525 (497-3039)0.0009Median PicA, D-Dimer05100-2339)0.255 (497-3039)0.0005Median PicA, Procalcitonin ng/mL on Admission0.10.255 (497-3039)0.0003Median PicA, Procalcitonin ng/mL on Admission0.10.3120.313Median PicA, Procalcitonin ng/mL on Admission0.10.3120.313Median PicA, CRP3.3 (3.5-19.6)6.4 (4.3-25.1)0.312Median PicA, Procalcitonin m	COPD, #	5	2	1.000
Henodialysis, #110430Number hospitalized630.6300.630# of influenza tests, viral panels, result12 and 3 respectively, NEG6 and 3 respectively, NEG10.000Azithromycin, #1420.6600.600Doxycycline, #630.600Beta lactam antibiotics, #010.240Steroids given, #010.240Hotiony of ACEI/ARB use411.000Median SAPS II score399 (150-2236)1525 (497-3039)0.009Median PEAK Do-Dimer465 (150-2339)2592 (887-3039)0.003Median PEAK Do-Dimer0.14.560.023Median PEAK Drocalcionin ng/mL on Admission0.14.560.023Median PEAK RP941880.003Median PEAK RP136 (19-1500)385 (249-1500)0.158Median PEAK RP136 (19-1500)385 (249-1500)0.158Median PEAK RP12 (0.7-10.6)0.7 (0.5-1.0)0.312Median PEAK Procalcinonin136 (19-1500)64 (385-1500)0.431Median PEAK Procalcinoning/mL136 (19-1500)85 (249-1500)0.431Median PEAK Procalcinoning/mL10 (0.7-1.0)0.312Median PEAK Procalcinoning/mL10 (0.7-1.0)0.312Median PEAK Procalcinoning/mL10 (0.8-2.79)0.230Median PEAK Procalcinoning/mL10 (0.8-2.79)0.231Median PEAK Procalcinoning/mL10 (0.8-2.79)0.231Median PEAK Procaline maydiL </td <td>CAD, #</td> <td>5</td> <td>3</td> <td>0.344</td>	CAD, #	5	3	0.344
Number hospitalized630.630# of influenza tests, viral panels, result12 and 3 respectively, NEG6 and 3 respectively, NEGHydroxychloroquine, #630.600Azithromycin, #630.600Doxycycline, #630.340Steroids given, #010.240History of ACEI/ARB use411.000Median SAPS II score399 (150-2226)525 (497-3039)0.009Median PicAlt D-Dimer465 (150-2339)2592 (887-3039)0.005Median PicAlt Procalcitonin ng/mL on Admission0.10.250.042Median PicAlt Procalcitonin ng/mL on Admission24740.000Median PicAlt Procalcitonin ng/mL on Admission136 (19-1500)383 (249-1500)0.013Median PicAlt Strine136 (19-1500)664 (335-1500)0.047Median PicAlt Strinin136 (19-1500)664 (335-1500)0.047Median PicAlt Strinin136 (19-1500)64 (43-25.1)0.230Median PicAlt Strinin12 (0.7-10.6)1.8 (0.8-6.3)0.045Median PicAlt Strinin12 (0.7-10.6)1.8 (0.8-6.3)0.025Median Strung Creatinine mg/dL1.1 (0.7-6.6)1.8 (0.8-6.3)0.05Median Strung Creatinine mg/dL2.00.1651.5 (2.9.1)0.25Norti types220.0050.047Median Strung Creatinine mg/dL1.1 (0.7-6.6)1.8 (0.8-6.3)0.05Norti types220.051.6 (2.9.1)0.02	Hemodialysis, #	1	1	0.430
# of influenza tests, viral panels, result12 and 3 respectively, NEG6 and 3 respectively, NEGHydroxychloroquine, #131.000Azithromycin, #630.600Doxycycline, #630.340Beta lactam antibiotics, #010.240Hydroxy of ACEI/ABB use410.000Median ASPS II score32770.0009Median ASPS II score65 (150-2339)0.252 (87-3039)0.019Median PEAK Procalcitonin g/mL on Admission0.10.250.422Median REAK Procalcitonin g/mL on Admission0.10.250.423Median PEAK Procalcitonin0.10.250.423Median PEAK Procalcitonin g/mL on Admission36 (19-100)385 (249-1500)0.015Median PEAK Repritin136 (19-1500)385 (249-1500)0.047Median PEAK Repritin136 (19-1500)64 (385-1500)0.047Median PEAK Repritin136 (19-100)385 (249-1500)0.047Median PEAK Repritin12 (0.710.6)0.7 (0.5-1.0)0.312Median Absolute Lymphocytes12 (0.710.6)0.7 (0.5-1.0)0.312Median Absolute Lymphocytes12 (0.710.6)0.0470.001Median DFAK10 (0.76.5.0)0.64 (199-320)0.052Median Absolute Lymphocytes200.015Median Absolute Lymphocytes200Median Absolute Lymphocytes200Median Absolute Lymphocytes200<	Number hospitalized	6	3	0.630
Hydroxychloroquine, # 11 3 1,000 Azithromycin, # 4 2 0.600 Azithromycin, # 6 3 0.6000 Beta lactam antibiotics, # 5 3 0.340 Steroids given, # 0 1 0.240 Itistory of ACEI/ARB use 4 1 0.0009 Median SAPS II score 3299 (150-2226) 47 0.0009 Median D-dimer on admission ng/mL 399 (150-2226) 552 (87-3039) 0.0005 Median PEAK D-Dimer 465 (150-239.3) 2592 (87-3039) 0.0005 Median PEAK D-Dimer 0.1 2.552 (87-3039) 0.0023 Median PEAK Procalcitonin ng/mL on Admission 0.1 4.56 0.023 Median PEAK Procalcitonin ng/mL on Admission 24 74 <0.001	# of influenza tests, viral panels, result	12 and 3 respectively, NEG	6 and 3 respectively, NEG	
Azitromycin, #420.606Doxycycline, #630.600Beta lactam antibiotics, #530.340Steroids given, #010.240History of ACEI/ARB use410.020Median SAPS II score32470.0009Median D-dimer on admission ng/mL399 (150-226)1525 (497-3039)0.019Median PEAK D-Dimer665 (150-2339)2592 (887-3039)0.0005Median PEAK Proclacitonin ng/mL on Admission0.10.250.042Median PEAK Proclacitonin ng/mL on Admission0.10.50.023Median PEAK Renz Dimer136 (19-1500)385 (249-1500)0.033Median PEAK RENZ126 (21-1500)664 (385-1500)0.047Median PEAK Renz Dimer126 (27-10.6)64 (43-25.1)0.230Median Absolute Lymphocytes1.2 (0.7-10.6)1.8 (0.68-6.3)0.015Median LDH U/L150 (89-279)264 (199-320)0.002blood types:10.20.0020.002O orgive220.0020.002A negative2220.002A negative22211A negative2021A positive20211A negative30011A negative61111Dositive22111A negative3	Hydroxychloroquine, #	11	3	1.000
Doxycycline, # 6 3 0.600 Beta lactarn antibiotics, # 5 3 0.340 Beta lactarn antibiotics, # 0 0 0.340 Steroids given, # 1 0.240 History of ACEI/ARB use 4 1 0.0009 Median APSI Iscore 399 (150-2226) 1525 (497-3039) 0.019 Median P-dimer on admission ng/mL 399 (150-2236) 2592 (887-3039) 0.0005 Median P-dimer on admission ng/mL 0.1 0.25 0.042 Median PEAK Procalcitonin 0.1 0.56 0.023 Median GRP mg/L on Admission 24 174 <0.001	Azithromycin, #	4	2	0.606
Beta lactam antibiotics, # 5 3 0.340 Steroids given, # 0 1 0.240 History of ACEI/ARB use 4 1.000 Median SAPS II score 32 7 0.0009 Median D-dimer on admission ng/mL 399 (150-2226) 1525 (497-3039) 0.0019 Median PEAK D-Dimer 465 (150-2339) 2592 (887-3039) 0.0022 Median PEAK Drocalcitonin ng/mL on Admission 0.1 0.25 0.042 Median RPEAK Procalcitonin ng/mL on Admission 0.1 4.56 0.023 Median Region Regi	Doxycycline, #	6	3	0.600
Steroids given, # 0 1 0.240 History of ACEI/ARB use 4 1 1.000 Median SAPS II score 32 47 0.0009 Median D-dimer on admission ng/mL 399 (150-2226) 1525 (497-3039) 0.019 Median PEAK D-Dimer 456 (150-2339) 2592 (887-3039) 0.0005 Median PEAK D-Dimer 456 (150-2339) 0.25 0.042 Median PEAK Procalcitonin ng/mL on Admission 0.1 0.25 0.042 Median PEAK Procalcitonin 0.1 0.25 0.042 Median PEAK Procalcitonin 0.1 0.25 0.042 Median PEAK Procalcitonin 0.1 4.56 0.023 Median PEAK Procalcitonin 136 (19-1500) 385 (249-1500) 0.047 Median PEAK Perritin 216 (21-1500) 64 (4.3-25.10) 0.230 Median Secture Lymphocytes 1.2 (0.7-10.6) 0.7 (0.5-1.0) 0.312 Median IDH IU/L 150 (89-279) 26 (19-320) 0.002 Iblood types: - - - O negative	Beta lactam antibiotics, #	5	3	0.340
History of ACEI/ARB use 4 1 1.000 Median SAPS II score 32 47 0.009 Median Dedimer on admission ng/mL 399 (150-2226) 1525 (497-3039) 0.019 Median Procalictonin ng/mL on Admission 465 (150-2339) 2592 (887-3039) 0.0005 Median Procalictonin ng/mL on Admission 0.1 0.25 0.042 Median Procalictonin ng/mL on Admission 0.1 4.56 0.033 Median PEAK Procalcitonin 24 0.003 0.003 Median PEAK CRP 49 188 0.003 Median PEAK Ferritin 36 (19-1500) 365 (249-1500) 0.158 Median PEAK Ferritin 216 (21-1500) 64 (385-1500) 0.230 Median PEAK Ferritin 210 (7-10.6) 0.7 (0.5-1.0) 0.312 Median Serum Creatinine mg/dL 1.1 (0.7-6.6) 1.8 (0.8-6.3) 0.165 Median Serum Creatinine mg/dL 1.0 (0.7-6.6) 1.8 (0.8-6.3) 0.165 Iblood types: 2 0 2 0 O negative 2 0 1	Steroids given, #	0	1	0.240
Median SAPS II score 32 47 0.0009 Median D-dimer on admission ng/mL 399 (150-2226) 1525 (497-3039) 0.019 Median PEAK D-Dimer 465 (150-2339) 2592 (887-3039) 0.002 Median PEAK D-Dimer 0.1 0.25 0.042 Median PEAK Procalcitonin ng/mL on Admission 0.1 4.56 0.023 Median PEAK Procalcitonin ng/L on Admission 24 174 <0.001	History of ACEI/ARB use	4	1	1.000
Median D-dimer on admission ng/mL 399 (150-2226) 1525 (497-3039) 0.019 Median PEAK D-Dimer 465 (150-2339) 2592 (887-3039) 0.0005 Median PEAK D-Dimer 0.1 2592 (887-3039) 0.042 Median PEAK Procelictonin 0.1 0.25 0.023 Median CRP mg/L on Admission 24 174 <0.001	Median SAPS II score	32	47	0.0009
Median PEAK D-Dimer 465 (150-2339) 2592 (887-3039) 0.0005 Median Procalcitonin ng/mL on Admission 0.1 0.25 0.042 Median PEAK Procalcitonin 0.1 4.56 0.023 Median PEAK Procalcitonin 24 74 <0.003	Median D-dimer on admission ng/mL	399 (150-2226)	1525 (497-3039)	0.019
Median Procalcitonin ng/mL on Admission 0.1 0.25 0.042 Median PEAK Procalcitonin 0.1 4.56 0.023 Median CRP ng/L on Admission 24 174 <0.001	Median PEAK D-Dimer	465 (150-2339)	2592 (887-3039)	0.0005
Median PEAK Procalcitonin 0.1 4.56 0.023 Median CRP mg/L on Admission 24 174 <0.001	Median Procalcitonin ng/mL on Admission	0.1	0.25	0.042
Median CRP mg/L on Admission 24 174 <0.001	Median PEAK Procalcitonin	0.1	4.56	0.023
Median PEAK CRP 49 188 0.003 Median Ferritin on Admission ng/mL 136 (19-1500) 385 (249-1500) 0.158 Median PEAK Ferritin 216 (21-1500) 664 (385-1500) 0.047 Median White Blood Cells/mm3 53 (3.5-19.6) 64 (4.3-25.1) 0.230 Median Absolute Lymphocytes 1.2 (0.7-10.6) 0.7 (0.5-1.0) 0.312 Median Serum Creatinine mg/dL 1.1 (0.7-6.6) 1.8 (0.8-6.3) 0.162 Median LDH IU/L 150 (89-279) 264 (199-320) 0.002 blood types: 2 0 0.002 o negative 2 0 0.002 A negative 2 0 0 A negative 2 0 1 AB positive 4 0 1 AB positive 4 0 1 AB positive 4 1 1 1	Median CRP mg/L on Admission	24	174	< 0.001
Median Ferritin on Admission ng/mL 136 (19-1500) 385 (249-1500) 0.158 Median PEAK Ferritin 216 (21-1500) 664 (385-1500) 0.047 Median White Blood Cells/mm3 5.3 (3.5-19.6) 6.4 (4.3-25.1) 0.230 Median Absolute Lymphocytes 1.2 (0.7-10.6) 0.7 (0.5-1.0) 0.312 Median LDH IU/L 150 (89-279) 264 (199-320) 0.002 blood types: 2 0 0.002 O negative 2 2 0 A negative 2 0 1 B negative 1 0 0 A positive 4 0 1 Median Median LDH IU/L 0 0 1 Unknown 6 1 1 1	Median <u>PEAK</u> CRP	49	188	0.003
Median PEAK Ferritin 216 (21-1500) 664 (385-1500) 0.047 Median White Blood Cells/mm3 5.3 (3.5-19.6) 6.4 (4.3-25.1) 0.230 Median Absolute Lymphocytes 1.2 (0.7-10.6) 0.7 (0.5-1.0) 0.312 Median LDH RU/L 1.0 (0.7-6.6) 1.8 (0.8-6.3) 0.165 blood types: 10 (0.9-279) 264 (199-320) 0.002 o negative 2 2 0 1.0 (0.002) 0.002 A positive 2 0 2 1.0 (0.002) 0.002 B negative 2 0 2 1.0 (0.002)<	Median Ferritin on Admission ng/mL	136 (19-1500)	385 (249-1500)	0.158
Median White Blood Cells/mm3 5.3 (3.5-19.6) 6.4 (4.3-25.1) 0.230 Median Absolute Lymphocytes 1.2 (0.7-10.6) 0.7 (0.5-1.0) 0.312 Median Serum Creatinine mg/dL 1.1 (0.7-6.6) 1.8 (0.8-6.3) 0.165 Median LDH IU/L 150 (89-279) 264 (199-320) 0.002 blood types: 2 0 2 0 O negative 2 0 2 0 2 A negative 2 0 2 2 0 2 2 0 2 2 2 2 2 3 <td< td=""><td>Median <u>PEAK</u> Ferritin</td><td>216 (21-1500)</td><td>664 (385-1500)</td><td>0.047</td></td<>	Median <u>PEAK</u> Ferritin	216 (21-1500)	664 (385-1500)	0.047
Median Absolute Lymphocytes 1.2 (0.7-10.6) 0.7 (0.5-1.0) 0.312 Median Serum Creatinine mg/dL 1.1 (0.7-6.6) 1.8 (0.8-6.3) 0.165 Median LDH IU/L 150 (89-279) 264 (199-320) 0.002 blood types: 2 0 0 0.002 O negative 2 0 0 0 A positive 2 0 2 0 A negative 2 0 0 1 AB positive 4 0 1 1 Median LDH LDH LDH 6 1 1 1 1	Median White Blood Cells/mm3	5.3 (3.5-19.6)	6.4 (4.3-25.1)	0.230
Median Serum Creatinine mg/dL 1.1 (0.7-6.6) 1.8 (0.8-6.3) 0.165 Median LDH IU/L 150 (89-279) 264 (199-320) 0.002 blood types: 2 2 0 2 0 0 1 0	Median Absolute Lymphocytes	1.2 (0.7-10.6)	0.7 (0.5-1.0)	0.312
Median LDH IU/L 150 (89-279) 264 (199-320) 0.002 blood types: 0.002 O positive 2 2 <td>Median Serum Creatinine mg/dL</td> <td>1.1 (0.7-6.6)</td> <td>1.8 (0.8-6.3)</td> <td>0.165</td>	Median Serum Creatinine mg/dL	1.1 (0.7-6.6)	1.8 (0.8-6.3)	0.165
blood types:O positive2O negative2A positive2A negative2B negative0A B positive4Unknown6	Median LDH IU/L	150 (89-279)	264 (199-320)	0.002
O positive22O negative20A positive22A negative20B negative00AB positive41Unknown61	blood types:			
O negative20A positive22A negative20B negative10AB positive41Unknown61	O positive	2	2	
A positive22A negative20B negative10AB positive41Unknown61	O negative	2	0	
A negative20B negative10AB positive41Unknown61	A positive	2	2	
B negative10AB positive41Unknown61	A negative	2	0	
AB positive41Unknown61	B negative	1	0	
Unknown 6 1	AB positive	4	1	
	Unknown	6	1	

ACEI, ace inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive lung disease; CRP, C-reactive protein; LDH, lactate dehydrogenase; NEG, negative; SAPS II, simplified acute physiologic score II; SBP, systolic blood pressure.

hospitalized, 6 died. The mortality rate was 24%. No coinfection with influenza or other respiratory viruses was identified. Table 1 summarizes the demographic characteristics, medical history and laboratory findings of the patients. The median age was 74 years, with no difference in age between recovered and diseased, 73 vs 77, *P*: .105. Simplified acute physiology score II was higher in the deceased group (*P*: .001) and so were D-dimer (admission and peak levels), C-reactive protein, lactate dehydrogenase, and peak ferritin and procalcitonin levels. See Table 1. During this outbreak, 11 HCPs were diagnosed with COVID 19 and all recovered. Among the patients who recovered, 13 had persistent positive nasopharyngeal RT-PCR for average 32 days (range 19-52 days) since diagnosis. Seven out of these 13 were tested for SARS-COV-2 IgG antibody (Abbott, Lake Forrest, IL) and were all positive.

DISCUSSION

The median incubation period for a symptomatic SARS-CoV-2 infection is 5 days; symptoms can appear within 12 days of

infection.¹¹ This novel coronavirus can be transmitted by an asymptomatic carrier; Arons et al showed that half of the residents in a skilled nursing facility who tested positive for the virus were asymptomatic. This was likely contributing to the transmission, as focusing infection control strategies solely on symptomatic residents failed to prevent transmission.¹² By closely reviewing Figure 2, the epidemiologic analysis of this outbreak likely suggests introduction of the virus in the units via an asymptomatic carrier (healthcare worker, family member) which then lead to fast propagation among staff and residents. Transmission between residents was likely aided by sharing of double occupancy rooms, participating in group activities, including community dining, and utilizing similar resources. For example, cases 1 and 4 had been using the dialysis unit on our campus. Notably, a subsequent COVID-19 outbreak took place by end of March in this dialysis unit.

In our experience, after the initial rapid spread, formation of a geographic COVID unit within the CLC 1, assignment of a dedicated clinical team, and use of a rapid RT-PCR test had all been instrumental

ARTICLE IN PRESS

in aiding this outbreak containment. Dora et al also demonstrated how effective the creation of a COVID unit inside the nursing home can be; cohorting of cases allowed for residents to stay in familiar grounds, enabled the restriction of staff movement between the wards, and overall reduced the potential of viral transmission.¹³ Universal testing of residents (first aiming close neighboring residents and then every resident) and HCPs was another principal measure to successfully interrupt the outbreak. Eckardt et al demonstrated that a productive structured 14-day interval universal testing in their long-term care facility aided to contain the spread of the virus in a 6-week period.¹⁴ Implementing the measures described above we managed to suppress the outbreak within 3 weeks in both CLC 1 and 2. At this writing there are no active COVID-19 cases in our CLCs.

We followed the CDC's proposed test-based strategy to remove COVID-19 precaution/isolation measures. This had the unfortunate effect of keeping residents longer on strict isolation as their RT-PCR tests remained positive, even though they had recovered or remained asymptomatic and had also developed an IgG antibody. The CDC has since updated their guidelines regarding discontinuation of transmission-based precautions, no longer requiring a test-based strategy for asymptomatic or patients with mild disease.¹⁵

Prolonged positive SARS-CoV-2 RT-PCRs, up to 5 weeks, have been reported in many studies; the RNA detected in these cases is likely from nonviable virus. A proposed way of how to interpret the PCR test in these cases is to utilize the cycle threshold (Ct) value.¹⁶ This value is not reported to the clinician but can be reported upon request. It is part of the RT-PCR test, with a specified threshold for a positive result, and it is inversely related with the viral load. A Ct value of >34 likely denotes non transmissible disease.¹⁶ Exploring this potential strategy in more rigorous studies could shorten duration of isolation, conserve tests, reagents, and PPE.

In conclusion, SARS-CoV-2 infection can spread rapidly within skilled nursing facilities and can potentially cause high morbidity and mortality. Swift detection by rapid RT-PCR testing of all asymptomatic carriers (residents and employees via universal testing) and implementation of strict infection control and isolation measures are pivotal in containing and thus eliminating a COVID-19 outbreak. Indeed, the infection control team working closely with the dedicated nursing home staff, are both the unsung heroes of the robust and unyielding defense against a formidable virus.

Acknowledgments

The authors would like to thank our Veterans, and the nursing home staff, the facility leadership, the laboratory staff for their help during this pandemic.

References

- Cucinotta D, Venelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020;91:157–160.
- McMichael TM, Currie DW, Clark S, et al. Epidemiology of Covid-19 in a long-term care facility in King County, Washington. N Engl J Med. 2020;383:2005–2011.
- Available at: https://coronavirus.jhu.edu/map.html. Accessed August 12, 2020.
 Perrota F, Corbi G, Mazzeo G, et al. COVID-19 and the elderly: insights into patho-
- genesis and clinical decision-making [published correction appears in Aging Clin Exp Res. 2020 Sep;32(9):1909]. Aging Clin Exp Res. 2020;32:1599–1608.
- Available at: https://data.cms.gov/stories/s/COVID-19-Nursing-Home-Data/bkwz-xpvg/ Accessed September 8, 2020.
- Abrams HR, Loomer L, Gandhi A, Grabowski DC. Characteristics of U.S. nursing homes with COVID-19 cases. J Am Geriatr Soc. 2020;68:1653–1656.
- 7. Yancy CW. COVID-19 and African Americans. *JAMA*. 2020;323:1891–1892.
- Spotswood S. VA touts lower CLC COVID-19 rates vs. community nursing homes. 2020. U.S Medicine. 56:15. Available at: https://www.usmedicine.com/late-break ing-news/va-touts-lower-clc-covid-19-rates-vs-community-nursing-homes/. Accessed August 12, 2020.
- Centers for Medicare & Medicaid Services. COVID-19 Long-Term Care Facility Guidance. Washington, DC. Available at: US Department of Health and Human Services, Centers for Medicare and & Medicaid Services; 2020. https://www.cms.gov/files/ document/4220-covid-19-long-term-care-facility-guidance.pdf. Accessed November 10, 2020.
- Centers for Disease Control and Prevention. Testing guidance for nursing homes. Interim SARS-CoV-2 testing guidelines for nursing home residents and healthcare personnel. 2020. Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/ nursing-homes-testing.html. Accessed August 12, 2020.
- Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. *Ann Intern Med*. 2020;172:577–582.
- Arons MM, Hatfield KM, Reddy SC, et al. Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. N Engl J Med. 2020;382:2081–2090.
- Dora AV, Winnett A, Jatt LP, et al. Universal and serial laboratory testing for SARS-CoV-2 at a long-term care skilled nursing facility for veterans - Los Angeles, California, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:651–655.
- Eckardt P, Guran R, Hennmyre J, et al. Hospital affiliated long term care facility COVID-19 containment strategy by using prevalence testing and infection control best practices [e-pub ahead of print]. *Am J Infect Control*. https://doi.org/10.1016/j. ajic.2020.06.215. Accessed November 10, 2020.
- Centers for Disease Control and Prevention. Discontinuation of transmission-based precautions and disposition of patients with COVID-19 in healthcare settings (interim Guidance). Available at: https://www.cdc.gov/coronavirus/2019-ncov/ hcp/disposition-hospitalized-patients.html. Accessed August 12, 2020.
- Tom MR, Mina MJ. To interpret the SARS-COV-2 test, consider the cycle threshold value [e-pub ahead of print]. Clin Infect Dis. doi:https://doi.org/10.1093/cid/ ciaa619. Accessed November 10, 2020.